Want to see CLGN full AI Analyst Report?

Collplant Holdings (CLGN) Earnings Dates, Call Summary & Reports

182 Followers

Earnings Data

Report Date

Aug 20, 2026

TBA (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

―

Last Year’s EPS

-0.28

Same Quarter Last Year

Analyst Consensus

―

Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2024

Earnings Call Date:Mar 26, 2025|

% Change Since:

Earnings Call Sentiment|Neutral

Despite significant advancements in preclinical programs and continued collaboration with AbbVie, the company experienced a sharp decline in annual revenue and increased net losses, presenting a mixed financial outlook.

Company Guidance

During the CollPlant Biotechnologies Ltd. investor call, CEO Yehiel Tal and Deputy CEO Eran Rotem provided guidance centered on their regenerative medicine advancements, notably highlighting their proprietary photocurable dermal filler and regenerative breast implant programs. The dermal filler, aimed at a market valued at approximately $6.3 billion with a 10% CAGR, is currently in the preclinical phase, with plans to launch a clinical trial within two years. The regenerative breast implant program is progressing with preclinical testing of 250cc commercial-sized prototypes, showing promising results in tissue integration without complications. Financially, CollPlant reported a decrease in revenue from $11 million in 2023 to $515,000 in 2024, primarily due to a $10 million milestone payment from AbbVie in 2023. Despite a GAAP net loss of $16.6 million in 2024 compared to $7 million in 2023, the company maintains a stable cash position of $11.9 million as of December 31, 2024, not accounting for an additional $2 million payment from AbbVie, ensuring operational capability into the second quarter of 2026.

Photocurable Dermal Filler Preclinical Success

The photocurable dermal filler candidate is in the preclinical phase, targeting a market valued at approximately $6.3 billion with a compound annual growth rate of 10%. Positive feedback from leaders in aesthetic medicine suggests it could be a game-changer for facial plastic surgery.

Regenerative Breast Implant Program Progress

Preclinical testing of commercial-sized breast implants (250cc) shows promising outcomes with depolarization and rapid tissue ingrowth, no complications, and maintained volume retention. This product could revolutionize breast reconstruction and aesthetic enhancements.

AbbVie Collaboration and Financial Milestone

CollPlant received a $2 million payment from AbbVie following development achievements in their dermal filler clinical trials, indicative of continued collaboration and potential future milestones.

Cash Runway Stability

Cash and cash equivalents as of December 31, 2024, were $11.9 million, with an expected operational runway through the second quarter of 2026.

Collplant Holdings (CLGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CLGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 20, 2026	2026 (Q2)	- / -	-0.28	―	―	―
May 29, 2026	2026 (Q1)	-0.24 / -0.23	-0.13	-76.92% (-0.10)	―	―
Mar 26, 2026	2025 (Q4)	-0.30 / -0.25	-0.33	24.24% (+0.08)	―	―
Nov 26, 2025	2025 (Q3)	0.15 / -0.27	-0.38	28.95% (+0.11)	―	―
Aug 20, 2025	2025 (Q2)	-0.10 / -0.28	-0.37	24.32% (+0.09)	―	―
May 28, 2025	2025 (Q1)	-0.04 / -0.13	-0.37	64.86% (+0.24)	―	―
Mar 26, 2025	2024 (Q4)	-0.13 / -0.33	-0.4	17.50% (+0.07)	―
Nov 27, 2024	2024 (Q3)	-0.28 / -0.38	-0.38	0.00% (0.00)	―
Aug 20, 2024	2024 (Q2)	-0.27 / -0.37	0.49	-175.51% (-0.86)	―
May 29, 2024	2024 (Q1)	- / -	-0.33	―	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CLGN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 29, 2026	$0.41	$0.40	-0.74%
Mar 26, 2026	$0.75	$0.66	-12.00%
Nov 26, 2025	$2.24	$2.23	-0.45%
Aug 20, 2025	$2.46	$1.97	-20.20%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Collplant Holdings (CLGN) report earnings?

Collplant Holdings (CLGN) is schdueled to report earning on Aug 20, 2026, TBA (Confirmed).

What is Collplant Holdings (CLGN) earnings time?

Collplant Holdings (CLGN) earnings time is at Aug 20, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CLGN EPS forecast?

Currently, no data Available